Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Issue of Equity

21 Jul 2006 07:00

ReGen Therapeutics PLC21 July 2006 ReGen Therapeutics Plc places 111,000,000 of shares ReGen Therapeutics Plc ("ReGen" or the "Company") announces that it has todayplaced through its brokers J M Finn & Co with new and existing shareholders111,000,000 new ordinary shares at 1p per share to raise £1,110,000, beforeexpenses ("Placing") Application will be made for these 111,000,000 new ordinary shares to beadmitted to the AIM Market of the London Stock Exchange Plc and dealings areexpected to commence at 8am on 27th July 2006. Executive Chairman Percy Lomax commented, "This money will be used for thecommercialisation of Colostrinin(TM)as per the recently announced deal withMetagenics Inc. and carry out further work on the development of its constituentpeptides as potential pharmaceuticals as well as providing additional resourcesfor the development of new formulations of zolpidem for the rehabilitation ofpeople with brain injury. This has received considerable positive publicity inthe national press and a documentary film is currently being discussed with anumber of producers. Depending upon the actual timing of anticipated revenuesfrom the commercialisation of ColostrininTM, the achievement of developmentmilestones and whether other commercial opportunities present themselves, it maybe necessary to raise additional amounts of capital in the future." All new ordinary shares will rank pari passu with the existing ordinary shares of 0.1p each in the Company. Two Non-Executive Directors are subscribing for new ordinary shares in theplacing: Mr Peter Garrod is subscribing for 2,500,000 new ordinary shares makinghis total holding 66,250,000 representing 9.54% of the enlarged share capital.Mr Keith Corbin is subscribing for 1,000,000 new ordinary shares making histotal holding 1,105,000 representing 0.16% of the enlarged share capital. For further information, please contact: Andrew MarshallGreycoat CommunicationsTel. 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Sep 20207:00 amRNSClinical Study with Nasally Administered Foralumab
16th Sep 20209:05 amRNSSecond Price Monitoring Extn
16th Sep 20209:00 amRNSPrice Monitoring Extension
16th Sep 20207:00 amRNSDemerger of StemPrintER and Distribution in Specie
7th Sep 202011:05 amRNSSecond Price Monitoring Extn
7th Sep 202011:00 amRNSPrice Monitoring Extension
2nd Sep 20204:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20204:35 pmRNSPrice Monitoring Extension
2nd Sep 20202:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20202:00 pmRNSPrice Monitoring Extension
28th Aug 202012:04 pmRNSHolding(s) in Company
28th Aug 202010:30 amRNSADS Registration Statement Filing Clarification
27th Aug 20204:00 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20207:00 amRNSTiziana CEO Interview
26th Aug 20207:00 amRNSGrant of Options - Director Dealings
24th Aug 20207:00 amRNSPatent Granted for Anti-IL-6/IL-6
21st Aug 20207:00 amRNSPatent Granted for Milciclib
20th Aug 20207:00 amRNSUpdate - Scientific Advisory Board
18th Aug 20209:05 amRNSSecond Price Monitoring Extn
18th Aug 20209:00 amRNSPrice Monitoring Extension
18th Aug 20207:00 amRNSPatent Granted for Foralumab
11th Aug 20208:49 amRNSBTIG's Virtual Biotechnology Conference
10th Aug 20207:00 amRNSHolding(s) in Company
5th Aug 20204:00 pmRNSClosing of $57.25 Million Offering
4th Aug 20207:00 amRNSExpedited Clinical Development Plan
3rd Aug 20207:00 amRNSIssue of Equity
31st Jul 20205:00 pmRNSTotal Voting Rights
31st Jul 20204:41 pmRNSSecond Price Monitoring Extn
31st Jul 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20207:00 amRNSSubmission of a Patent Application for Foralumab
30th Jul 20204:30 pmRNSProposed Admission to the Official List
30th Jul 202011:53 amRNSUpdate on Timings and Corporate Actions
30th Jul 20207:00 amRNSInvestor Webinar to Provide Corporate Updates
29th Jul 20202:05 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
24th Jul 20207:00 amRNSExercise of Warrants and Issue of Equity
20th Jul 20202:51 pmRNSDirector Appointment
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
16th Jul 202011:39 amRNSResult of AGM
16th Jul 20207:00 amRNSSubmission of Patent Application
15th Jul 20204:29 pmRNSChange to ADS Ratio - Updated
15th Jul 20201:00 pmRNSChange to ADS Ratio
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:41 pmRNSSecond Price Monitoring Extn
13th Jul 20204:36 pmRNSPrice Monitoring Extension
10th Jul 20206:01 pmRNSInterview to Air on Bloomberg International
1st Jul 20207:00 amRNSTotal Voting Rights and StemPrintER Update
29th Jun 202011:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.